Conference Correspondent

Serious Infections among Patients with Lupus Who Receive Corticosteroids and Immunosuppressants

Conference Correspondent - Conference Correspondent

Approximately 50% of patients with systemic lupus erythematosus (SLE) have a serious infection during their disease course, and infections are the leading causes of hospitalization and mortality in these patients. Using a Medicaid database system with billing and demographic information for more than 24 million enrollees, Feldman and colleagues (ACR 2013; Abstract 780)  identified 43,351 patients with prevalent SLE who were being treated with either a corticosteroid alone or a corticosteroid plus an immunosuppressant (either azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, or tacrolimus).

During follow-up, the researchers identified 13,986 serious bacterial infections, including bacteremia (23%), pneumonia (38%), and cellulitis (24%). There were also 47 cases of pneumocystosis, 382 cases of herpes zoster infection, and 114 cases of influenza, all requiring hospitalization. The incidence rate for all infections was 1.2 times higher among patients with SLE who received a corticosteroid alone or a corticosteroid plus an immunosuppressant compared with those not being treated with these agents.

The incidence of viral infections was 2.4 times higher in patients with SLE who received an immunosuppressant and a corticosteroid, and 1.3 times higher with a corticosteroid alone, compared with patients who received neither treatment. Further studies are needed to evaluate the causality of these observed associations between drugs used to treat SLE and the increased risk for infection.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME